

Singapore's ASLAN pharma inks MoU with NCCS

20 July 2015 | News | By BioSpectrum Bureau

Singapore's ASLAN pharma inks MoU with NCCS



Singapore: ASLAN Pharmaceuticals has inked a memorandum of understanding with Singapore's National Cancer Center (NCCS) to develop newer therapies and intensify research of novel agents for the treatment of gastric cancer, hepatocellular carcinoma (liver) and cholangiocarcinoma (bile duct), three common forms of gastrointestinal (GI) cancers that are particularly prevalent in Asia.

As per the terms, collaborative projects focused on increasing the understanding of newer therapies to treat tumors will be initiated by ASLAN and NCCS. In addition, the parties will jointly conduct clinical trials studying novel treatments for Asia-prevalent cancers.

In collaboration with NCCS, ASLAN also plans to organize a symposium to encourage a broader clinical understanding of gastric cancers in the region. The disease symposiums, which will include a dedicated biannual cholangiocarcinoma symposium in Singapore, will bring together GI cancer scientists and clinicians to share research breakthroughs and facilitate knowledge exchange.

Professor Soo Khee Chee, director, NCCS added "We are delighted to be working with another Singapore-based pharmaceutical company to help develop new treatment for especially the difficult cancers that we encounter in our region."

Dr Bertil Lindmark, chief scientific officer of ASLAN, said, "There is a pressing need to address the inadequate treatment options for GI cancers and we are delighted to be strengthening our relationship with NCCS to explore novel treatment combinations which have the potential to displace traditional chemotherapy options. Our highly-experienced team has a

broad understanding of the epidemiological trends specific to cancer in Asia and, leveraging the world-class research capabilities of NCCS, we are well-positioned to accelerate treatment options for patients in the region and globally."